Background: Respiratory syncytial virus (RSV) infection in childhood, particularly in premature infants, is associated with significant morbidity and mortality.
Objectives: To compare the hospitalization rates due to RSV infection and severity of disease between infants with and without Down syndrome (DS) born at term and without other associated risk factors for severe RSV infection.
Patients/methods: In a prospective multicentre epidemiological study, 93 infants were included in the DS cohort and 68 matched by sex and data of birth (±1 week) and were followed up to 1 year of age and during a complete RSV season.
Results: The hospitalization rate for all acute respiratory infection was significantly higher in the DS cohort than in the non-DS cohort (44.1% vs 7.7%, P<.0001). Hospitalizations due to RSV were significantly more frequent in the DH cohort than in the non-DS cohort (9.7% vs 1.5%, P=.03). RSV prophylaxis was recorded in 33 (35.5%) infants with DS. The rate of hospitalization according to presence or absence of RSV immunoprophylaxis was 3.0% vs 15%, respectively.
Conclusions: Infants with DS showed a higher rate of hospitalization due to acute lower respiratory tract infection and RSV infection compared to non-DS infants. Including DS infants in recommendations for immunoprophylaxis of RSV disease should be considered.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5304568 | PMC |
http://dx.doi.org/10.1111/irv.12431 | DOI Listing |
J Virol
January 2025
Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands.
Human metapneumovirus (HMPV) is an important causative agent of respiratory tract disease. Fundamental knowledge of the interaction between HMPV and the innate immune system could lead to the design of novel antiviral therapies. Previously, we demonstrated that HMPV M2-2 deletion mutants had hypermutated genomes and contained defective interfering particles (DIs), which are potent inducers of the IFN response.
View Article and Find Full Text PDFJ Virol
January 2025
Institute of Virology and AIDS Research, The First Hospital of Jilin University, Changchun, Jilin, China.
Unlabelled: Respiratory syncytial virus (RSV) infections continue to plague infants, young children, and older individuals worldwide. Since there is no specific treatment for RSV, characterizing the interactions between RSV and host factors remains crucial for the eventual development of robust therapeutic interventions. In our previous study, guanylate binding protein 5 (GBP5) was shown to promote excessive RSV-small hydrophobic (RSV-SH) protein secretion by microvesicles and inhibited viral replication.
View Article and Find Full Text PDFmBio
January 2025
American Society for Microbiology, Washington, DC, USA.
mBio
January 2025
Cummings Life Sciences Center, The University of Chicago, Chicago, Illinois, USA.
Respiratory syncytial virus (RSV) was discovered in 1956 by the laboratory of Robert Chanock after its isolation from children with upper respiratory infections. Here, we review the events leading to its discovery including its prior isolation as chimpanzee coryza virus and its subsequent association with human disease.
View Article and Find Full Text PDFFront Pediatr
January 2025
Cluster for Health Services Research, Norwegian Institute of Public Health, Oslo, Norway.
Aim: Healthcare services are in need of tools that can help to ensure a sufficient capacity in periods with high prevalence of respiratory tract infections (RTIs). During the COVID-19 pandemic, we forecasted the number of hospital admissions for RTIs among children aged 0-5 years. Now, in 2024, we aim to examine the accuracy and usefulness of our forecast models.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!